| [1] |
Wilson JD, George FW, Griffin JE. The hormonal control of sexual development[J]. Science, 1981, 211(4488):1278–1284.
|
| [2] |
Teixeira J, Maheswaran S, Donahoe PK. Mullerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications[J]. Endocr Rev, 2001, 22(5):657–674.
|
| [3] |
Salhi I, Cambon-Roques S, Lamarre I, et al. The anti-Mullerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand[J]. Biochem J, 2004, 379(Pt 3):785–793.
|
| [4] |
de Vet A, Laven JSE, de Jong FH, et al. Anti-Mullerian Hormone serum levels: A putative marker for ovarian aging[J]. Fertil Steril, 2002, 77(2):357–362.
|
| [5] |
Hansen KR, Hodnett GM, Knowlton N, et al. Correlation of ovarian reserve tests with histologically determined primordial follicle number[J]. Fertil Steril, 2011, 95(1):170–175.
|
| [6] |
Hagen CP, Aksglaede L, Sorensen K, et al. Serum levels of anti-Mullerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients[J]. J Clin Endocrinol Metab, 2010, 95(11):5003–5010.
|
| [7] |
Kelsey TW, Wright P, Nelson SM, et al. A validated model of serum anti-mullerian hormone from conception to menopause[J]. PLoS One, 2011, 6(7):e22024.
|
| [8] |
Lie Fong S, Visser JA, Welt CK, et al. Serum anti-mullerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood[J]. J Clin Endocrinol Metab, 2012, 97(12):4650–4655.
|
| [9] |
teVelde ER, Pearson PL. The variability of female reproductive ageing[J]. Hum Reprod Update, 2002, 8(2):141–154.
|
| [10] |
Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences[J]. Endocr Rev, 2009, 30(5):465–493.
|
| [11] |
Broer SL, Eijkemans MJ, Scheffer GJ, et al. Anti-mullerian hormone predicts menopause: along-term follow-up study in normoovulatorywomen[J]. J Clin Endocrinol Metab, 2011, 96(8):2532–2539.
|
| [12] |
Freeman EW, Sammel MD, Lin H, Gracia CR. Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women[J]. J Clin Endocrinol Metab, 2012, 97(5):1673–1680.
|
| [13] |
Dolleman M, Faddy MJ, van Disseldorp J, et al. The relationship between anti-Mullerian hormone in women receiving fertility assessments and age at menopause in subfertile women: evidence from large population studies[J]. J Clin Endocrinol Metab, 2013a 98(5):1946–1953.
|
| [14] |
Dewailly D, Gronier H, Poncelet E, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries[J]. Hum Reprod, 2011, 26(11):3123–3129.
|
| [15] |
Dewailly D, Lujan ME, Carmina E, et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society[J]. Hum Reprod Update, 2014, 20(3):334–352.
|
| [16] |
Eilertsen TB, Vanky E, Carlsen SM. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced?[J]. Hum Reprod, 2012, 27(8):2494–2502.
|
| [17] |
Laven JS, Mulders AG, Visser JA, et al. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age[J]. J Clin Endocrinol Metab, 2004, 89(1):318–323.
|
| [18] |
Piouka A, Farmakiotis D, Katsikis I, et al. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels[J]. Am J Physiol Endocrinol Metab, 2009, 29–6(2):E238–E243.
|
| [19] |
Iliodromiti S, Kelsey TW, Anderson RA, et al. Can anti-mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data[J]. J Clin Endocrinol Metab, 2013, 98(8):3332–3340.
|
| [20] |
Baker VL. Primary ovarian insufficiency in the adolescent[J]. Curr Opin Obstet Gynecol, 2013, 25(5):375–381.
|
| [21] |
Leader B, Bakerb VL. Maximizing the clinical utility of antimullerian hormone testing in women’s health[J]. Curr Opin Obstet Gynecol, 2014, 26(4):226–236.
|
| [22] |
Lane AH, Lee MM, Fuller AF Jr, et al. Diagnostic utility of Mullerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors[J]. Gynecol Oncol, 1999, 73(1):51–55.
|
| [23] |
Mancaux A, GrardelChambenoit E, Gagneur O, et al. Granulosa cell tumor: difficulty of diagnosis and contribution of imaging[J]. Gynecol Obstet Fertil, 2013, 41(7–8):439–445.
|
| [24] |
Ha TU, Segev DL, Barbie D, et al. Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism[J]. J Biol Chem, 2000, 275(47):37101–37109.
|
| [25] |
Stephen AE, Pearsall LA, Christian BP, et al. Highly purified mullerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res, 2002, 8(8):2640–2646.
|
| [26] |
Berkenblit A, Cannistra SA. Advances in the management of epithelial ovarian cancer[J]. J Reprod Med, 2005, 50(6):426–438.
|
| [27] |
Renaud EJ, MacLaughlin DT, Oliva E, et al. Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance[J]. Proc Natl Acad Sci, 2005, 102(1):111–116.
|
| [28] |
Kim JH, MacLaughlin DT, Donahoe PK. Müllerian inhibiting substance/anti-Müllerian hormone: A novel treatment for gynecologic tumors[J]. Obstet Gynecol Sci, 2014, 57(5):343–357.
|
| [29] |
Yates AP, Rustamov O, Roberts SA, et al. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF[J]. Hum Reprod, 2011, 26(9):2353–2362.
|
| [30] |
La Marca A, Papaleo E, Grisendi V, et al. Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in vitro fertilisation cycles[J]. BJOG, 2012, 119(10):1171–1179.
|
| [31] |
Broer SL, van DJ, Broeze KA, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach[J]. Hum Reprod Update, 2013b 19(1):26–36.
|
| [32] |
Arce JC, La MA, Mirner KB, et al. Antimullerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients[J]. Fertil Steril, 2013, 99(6):1644–1653.
|
| [33] |
Brodin T, Hadziosmanovic N, Berglund L, et al. Antimullerian hormone levels are strongly associated with live-birth rates after assisted reproduction[J]. J Clin Endocrinol Metab, 2013, 98(3):1107–1114.
|
| [34] |
La Marca A, Nelson SM, Sighinolfi G, et al. Anti-Mullerian hormone-based prediction model for a live birth in assisted reproduction[J]. Reprod Biomed Online, 2011, 22(4):341–349.
|
| [35] |
Namkung J, Song JY, Jo HH, et al. Mullerian inhibiting substance induces apoptosis of human endometrial stromal cells in endometriosis[J]. J Clin Endocrinol Metab, 2012, 97(9):3224–3230.
|
| [36] |
Borahay MA, Lu F, Ozpolat B, et al. Mullerian inhibiting substance suppresses proliferation and induces apoptosis and autophagy in endometriosis cells in vitro[J]. ISRN Obstet Gynecol, 2013, 2013:361489.
|
| [37] |
Fabregues F, Castelo-Branco C, Carmona F, et al. The effect of differentvhormone therapies on antimullerian hormone serum levels in anovulatoryvwomen of reproductive age[J]. Gynecol Endocrinol, 2011, 27(4):216–224.
|
| [38] |
Mes-Krowinkel MG, Louwers YV, Mulders AG, et al. Influence of oral contraceptivesvonanthropomorphometric, endocrine, and metabolic profiles ofvanovulatory polycystic ovary syndrome patients[J]. Fertil Steril, 2014, 101(6):1757–1765.
|
| [39] |
Broer SL, Broekmans FJ, Laven JS, et al. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications[J]. Hum Reprod Update, 2014, 20(5):688–701.
|
| [40] |
Dolleman M, Verschuren WM, Eijkemans MJ, et al. Reproductive and lifestyle determinants of anti-Mullerian hormone in a large population-based study[J]. J Clin Endocrinol Metab, 2013b 98(5):2106–2115.
|